Barcelona, Spain
Chairman Medical Oncology Department
Vall d’Hebron University Hospital
Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is currently the Head of the Medical Oncology Department at the Vall d’Hebron University Hospital in Barcelona and the Director of the Vall d’Hebron Institute of Oncology.
He is also the head of the Gastrointestinal Tumors and Phase I Unit and is actively involved in translational research and pharmacodynamic phase I studies with molecular targeted therapies and related translational research, with a special focus on EGFR-family inhibitors and IGFR-PI3K-Akt-mTOR pathway inhibitors, and also in phase II and III studies with new chemotherapy agents in gastrointestinal tumors.
Based in the idea that each tumor has an independent genetic identity, the group he is leading very actively participates in the development of molecular therapies targeting specific oncoproteins, with the purpose of developing personalized therapies (e.g. against EGFR, HER2, BRAF, MEK, PI3K, Akt, mTOR or IGF1-R among others) for those patients displaying genetic lesions or pathway disregulation. One of the main objectives of the group is to identify new predictive markers of response to diverse treatments and to identify markers of primary resistance (de novo) and secondary treatment.
Dr. Tabernero is actively involved in different Editorial Boards. He has (co)authored approximately 250 peer-reviewed papers.
Dr. Tabernero serves as President of the European Society for Medical Oncology (ESMO).